ClinicalTrials.gg
CompletedNCT00843024Updated Jan 18, 2017Results posted

Migraine Study in Adolescent Patients

A Phase 3 interventional study of Sumatriptan and Naproxen Sodium and Placebo in Migraine Disorders, sponsored by GlaxoSmithKline. Completed at 79 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
589
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 42 studies testing sumatriptan in Migraine Disorders — none open to participants now, none under way, none of them phase 3. Sumatriptan · Migraine Disorders.

Enrollment
6th of 42
589 · median 74
Started
2008
with 3 others
Phase 3
18 of 42
none open now
Registered
15th of 42
by date
Lead sponsor
8 of 42
GlaxoSmithKline

Among the 42 studies testing sumatriptan in Migraine Disorders, this one is the 6th largest by enrollment, is one of 4 that started in 2008, is one of 18 in phase 3, and was the 15th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 341 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

None of the 42 studies testing sumatriptan in Migraine Disorders is open now. The open studies under Migraine Disorders, anywhere →

Where they have run

About sumatriptan

Sumatriptan: first FDA approval 1992 (IMITREX STATDOSE (AUTOINJECTOR)). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing sumatriptan in Migraine Disorders as a file.
02

Study summary

This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old

Read the detailed description

The purpose of this study is to determine whether the combination product, sumatriptan and naproxen sodium, is effective compared to placebo in the treatment of acute migraine in adolescent subjects 12-17 years old. Subjects will treat two migraine attacks over a \~25 week period.

03

Conditions studied

  • Migraine Disorders

Browse trials for

Keywords

  • Migraine with or without aura
  • Migraine efficacy
  • Migraine
  • Migraine headache
  • Adolescent migraine
  • TREXIMET
  • Sumatriptan succinate
  • Naproxen sodium
  • Migraine, acute
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Subjects eligible for enrollment in the study must meet all of the following criteria:

  1. Subject is >/=12 years of age and \</=17 years of age at the Screening Visit.
  2. Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1). A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required. Attacks should last a minimum of three hours and be associated with moderate-to-severe headache pain.
  3. Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches).
  4. Male or female subjects. Female subjects are eligible for participation in the study if they are:

    1. Females of non-; or
    2. Females of childbearing potential, and who have a negative urine pregnancy test at screening, and agree to use one of the GlaxoSmithKline (GSK)-specified highly effective methods for avoiding pregnancy
  5. Any subject taking oral at enrollment must be on a stable regimen for at least 2 months prior to screening.
  6. Subject and subject's parent or legal guardian are able to read and write English or Spanish.
  7. Subject is able to read, comprehend, and complete subject diaries.
  8. Subject's parent or legal guardian is willing and able to provide prior to subject entry into the study.
  9. Subject is willing and able to provide Informed Assent prior to entry into the study (if required).

    -

Exclusion Criteria:

  • Subjects meeting any of the following criteria must not be enrolled in the study:

    1. Subject is \< 74 pounds (33.3 kg).
    2. Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches.
    3. Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.
    4. Subject has uncontrolled hypertension at screening or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.
    5. Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a abnormality that, in the investigator's opinion, contraindicates participation in this study.
    6. Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above.
    7. Subject has evidence or history of central nervous system pathology including stroke and/or (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening.
    8. Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.
    9. Subject has , allergy, intolerance, or to the use of any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma.
    10. Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized.
    11. Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain. Regular use is defined as an average of 4 days per month over the last 6 months.
    12. Subject has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment.
    13. Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.
    14. Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease.
    15. Subject is pregnant, actively trying to become pregnant, or breast feeding or subject is not willing to have pregnancy test(s).
    16. Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.
    17. Subject has participated in any drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
589 participants (actual)

Study arms

  • Experimental
    Sumatriptan and Naproxen 1

    Sumatriptan succinate and naproxen sodium combination 10mg/60mg

    Drug: Sumatriptan and Naproxen Sodium

  • Experimental
    Sumatriptan and Naproxen 2

    Sumatriptan succinate and naproxen sodium combination 30mg/180mg

    Drug: Sumatriptan and Naproxen Sodium

  • Experimental
    Sumatriptan and Naproxen 3

    Sumatriptan succinate and naproxen sodium combination 85mg/500mg

    Drug: Sumatriptan and Naproxen Sodium

  • Placebo comparator
    Placebo

    Placebo to match

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Were Pain Free at 2 Hours Post-dose

    Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. Participants with pain-free response were considered as those who had a reduction in migraine headache pain from moderate (score=2) or severe (score=3) at baseline to none (score=0) post-treatment, without the use of rescue medication (additional medication taken by participants for the treatment of migraine pain or associated symptoms) prior to or at 2 hours post-dose.

    Time frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13)

Secondary outcomes

  1. Number of Participants Sustained Pain-free From 2-24 Hours

    Participants with sustained pain-freedom were defined as those with pain-freedom at 2 hours post-dose that was maintained up to 24 hours post-treatment without the use of rescue medication.

    Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)

  2. Number of Participants Photophobia-free at 2 Hours Post-dose

    The number of participants who did not have photophobia (sensitivity to light) at 2 hours post dose was analyzed.

    Time frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13)

  3. Number of Participants Phonophobia-free at 2 Hours Post-dose

    The number of participants who did not have phonophobia (sensitivity to sound) at 2 hours post dose was analzyed.

    Time frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13)

  4. Number of Participants Pain-free at 1 Hour Post-dose

    Participants with a pain-free response at 1 hour post-dose were considered as those who had a reduction in migraine headache pain from moderate (a score of 2) or severe (a score of 3) at baseline to none (a score of 0) post-treatment, without the use of rescue medication prior to or at 1 hour post dose.

    Time frame: 1 hour after single dose of double-blind treatment (Randomization through Week 13)

  5. Number of Participants Sustained Photophobia-free From 2-24 Hours

    Participants with sustained freedom from photophobia were those with an absence of photophobia (sensitivity to light) from 2 to 24 hours post-dose without the use of rescue medication.

    Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)

  6. Number of Participants Sustained Phonophobia-free From 2-24 Hours

    Participants with sustained freedom from phonophobia were those with an absence of phonophobia (sensitivity to sound) from 2 to 24 hours post-dose without the use of rescue medication.

    Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)

  7. Number of Participants Sustained Nausea-free From 2-24 Hours

    Participants with sustained freedom from nausea were those with an absence of nausea from 2 to 24 hours post-dose without the use of rescue medication.

    Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)

  8. Number of Participants Who Used Rescue Medication From 2 to 24 Hours Post Dose

    Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with investigational product. Permitted rescue medications included oral naproxen sodium (maximum 15 mg/kg), oral over-the-counter pain reliever, and anti-emetics. This outcome measure included only participants who rescued from 2 to 24 hours post-dose, inclusive.

    Time frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)

  9. Number of Participants Who Used Their First Dose of Rescue Medication Through the Indicated Time Points

    Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with double-blind treatment. In addition to participants who rescued from 2 to 24 hours post-dose, inclusive, this outcome measure also included nine protocol violators who rescued \< 2 hours post-treatment.

    Time frame: Dosing to 24 hours after single dose of double-blind treatment (Randomization through Week 13)

  10. Number of Participants Nausea-free at 2 Hours Post-dose

    The number of participants who did not have nausea at 2 hours post dose was analzyed.

    Time frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13)

Other outcomes

  1. Mean Age of Participants at Baseline Categorized by Age Group

    The mean age of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups.

    Time frame: Baseline

  2. Number of Participants Randomized to Double-blind Treatment in the Indicated Age Categories at Baseline

    The number of participants receiving double-blind treatment were reported according to age.

    Time frame: Baseline

  3. Number of Female and Male Participants Categorized by Age Group

    The gender of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups.

    Time frame: Baseline

  4. Number of Participants of the Indicated Race Categorized by Age Group

    The race of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups.

    Time frame: Baseline

  5. Mean Weight of Participants at Baseline Categorized by Age Group

    The mean weight of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups.

    Time frame: Baseline

  6. Mean Body Mass Index of Participants at Baseline Categorized by Age Group

    The mean body mass index of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups. Body mass index is calculated as: weight (kilograms \[kg\]) divided by height (meters \[m\]\^2).

    Time frame: Baseline

07

Results

Posted May 9, 2011

Participant flow

Single-blind Placebo Run-In Phase
Participant flow — Single-blind Placebo Run-In Phase
Milestone12 to 14 Years Age Group: Single-blind Phase15 to 17 Years Age Group: Single-blind PhasePlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Started4084570000
Completed2683210000
Not completed1401360000
Withdrew: Did not meet continuation criteria79740000
Withdrew: Lost to follow-up36310000
Withdrew: Withdrawal by subject19180000
Withdrew: Protocol violation450000
Withdrew: Physician decision260000
Withdrew: Adverse event010000
Withdrew: Other010000
Double-blind Treatment Phase
Participant flow — Double-blind Treatment Phase
Milestone12 to 14 Years Age Group: Single-blind Phase15 to 17 Years Age Group: Single-blind PhasePlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Started00176119117177
Completed001459697152
Not completed0031232025
Withdrew: No opportunity to treat migraine0020101314
Withdrew: Lost to follow-up008444
Withdrew: Withdrawal by subject000602
Withdrew: Protocol violation003003
Withdrew: Physician decision000311
Withdrew: Adverse event000011
Withdrew: Lack of efficacy000010

Outcome measures

PrimaryNumber of Participants Who Were Pain Free at 2 Hours Post-dose

Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. Participants with pain-free response were considered as those who had a reduction in migraine headache pain from moderate (score=2) or severe (score=3) at baseline to none (score=0) post-treatment, without the use of rescue medication (additional medication taken by participants for the treatment of migraine pain or associated symptoms) prior to or at 2 hours post-dose.

Time frame:
2 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Who Were Pain Free at 2 Hours Post-dose
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=142, 96, 97, 15014282636
12-14 years, n=70, 43, 46, 6510181317
15-17 years, n=72, 53, 51, 854101319
Statistical analysis
  • Placebo vs Sumatriptan 10 mg/ Naproxen 60 mg · Cochran-Mantel-Haenszel · p = 0.003 (Adjusted for multiplicity according to the fixed sequence testing strategy) · Mean difference (final values): 0.20 · 95% CI 0.09 to 0.30Sumatriptan 10 mg/Naproxen 60 mg minus placebo
  • Placebo vs Sumatriptan 30 mg/ Naproxen 180 mg · Cochran-Mantel-Haenszel · p = 0.003 (Adjusted for multiplicity according to the fixed-sequence testing strategy) · Mean difference (final values): 0.16 · 95% CI 0.07 to 0.26Sumatriptan 30 mg/Naproxen180 mg minus placebo
  • Placebo vs Sumatriptan 85 mg/ Naproxen 500 mg · Cochran-Mantel-Haenszel · p = 0.003 (Adjusted for multiplicity according to the fixed-sequence testing strategy) · Mean difference (final values): 0.13 · 95% CI 0.05 to 0.22Sumatriptan 85 mg/Naproxen 500 mg minus placebo
SecondaryNumber of Participants Sustained Pain-free From 2-24 Hours

Participants with sustained pain-freedom were defined as those with pain-freedom at 2 hours post-dose that was maintained up to 24 hours post-treatment without the use of rescue medication.

Time frame:
2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Sustained Pain-free From 2-24 Hours
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=142, 96, 97, 15013232435
12-14 years, n=70, 43, 46, 6510141217
15-17 years, n=72, 53, 51, 85391218
SecondaryNumber of Participants Photophobia-free at 2 Hours Post-dose

The number of participants who did not have photophobia (sensitivity to light) at 2 hours post dose was analyzed.

Time frame:
2 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Photophobia-free at 2 Hours Post-dose
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=144, 96, 96, 15159574789
12-14 years, n=71, 43, 46, 6533292441
15-17 years, n=73, 53, 50, 8626282348
SecondaryNumber of Participants Phonophobia-free at 2 Hours Post-dose

The number of participants who did not have phonophobia (sensitivity to sound) at 2 hours post dose was analzyed.

Time frame:
2 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Phonophobia-free at 2 Hours Post-dose
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=144, 96, 96, 15160595590
12-14 years, n=71, 43, 46, 6534323341
15-17 years, n=73, 53, 50, 8626472249
SecondaryNumber of Participants Pain-free at 1 Hour Post-dose

Participants with a pain-free response at 1 hour post-dose were considered as those who had a reduction in migraine headache pain from moderate (a score of 2) or severe (a score of 3) at baseline to none (a score of 0) post-treatment, without the use of rescue medication prior to or at 1 hour post dose.

Time frame:
1 hour after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Pain-free at 1 Hour Post-dose
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=142, 96, 97, 15069611
12-14 years, n=70, 43, 46, 654724
15-17 years, n=72, 53, 51, 852247
SecondaryNumber of Participants Sustained Photophobia-free From 2-24 Hours

Participants with sustained freedom from photophobia were those with an absence of photophobia (sensitivity to light) from 2 to 24 hours post-dose without the use of rescue medication.

Time frame:
2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Sustained Photophobia-free From 2-24 Hours
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=144, 96, 96, 15144484375
12-14 years, n=71, 43, 46, 6525212135
15-17 years, n=73, 53, 50, 8619272240
SecondaryNumber of Participants Sustained Phonophobia-free From 2-24 Hours

Participants with sustained freedom from phonophobia were those with an absence of phonophobia (sensitivity to sound) from 2 to 24 hours post-dose without the use of rescue medication.

Time frame:
2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Sustained Phonophobia-free From 2-24 Hours
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=144, 96, 96, 15147485179
12-14 years, n=71, 43, 46, 6527243136
15-17 years, n=73, 53, 50, 8620242043
SecondaryNumber of Participants Sustained Nausea-free From 2-24 Hours

Participants with sustained freedom from nausea were those with an absence of nausea from 2 to 24 hours post-dose without the use of rescue medication.

Time frame:
2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Sustained Nausea-free From 2-24 Hours
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=144, 95, 96, 15168676494
12-14 years, n=71, 43, 46, 6539313343
15-17 years, n=73, 52, 50, 8629363151
SecondaryNumber of Participants Who Used Rescue Medication From 2 to 24 Hours Post Dose

Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with investigational product. Permitted rescue medications included oral naproxen sodium (maximum 15 mg/kg), oral over-the-counter pain reliever, and anti-emetics. This outcome measure included only participants who rescued from 2 to 24 hours post-dose, inclusive.

Time frame:
2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Who Used Rescue Medication From 2 to 24 Hours Post Dose
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=145, 96, 97, 15247141621
12-14 years, n=71, 43, 46, 65215610
15-17 years, n=74, 53, 51, 872691011
SecondaryNumber of Participants Who Used Their First Dose of Rescue Medication Through the Indicated Time Points

Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with double-blind treatment. In addition to participants who rescued from 2 to 24 hours post-dose, inclusive, this outcome measure also included nine protocol violators who rescued \< 2 hours post-treatment.

Time frame:
Dosing to 24 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Who Used Their First Dose of Rescue Medication Through the Indicated Time Points
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, 1 hour, n=145, 96, 96, 1522002
Total Population, 2 hours, n=145, 96, 96, 15210063
Total Population, 3 hours, n=145, 96, 96, 1522961115
Total Population, 4 hours, n=145, 96, 96, 1523461316
Total Population, 8 hours, n=145, 96, 96, 1524591520
Total Population, 12 hours, n=145, 96, 96, 15248111520
Total Population, 18 hours, n=145, 96, 96, 15250131522
Total Population, 24 hours, n=145, 96, 96, 15252141723
12-14 years, 1 hour, n=71, 43, 46, 651000
12-14 years, 2 hours, n=71, 43, 46, 654011
12-14 years, 3 hours, n=71, 43, 46, 6511127
12-14 years, 4 hours, n=71, 43, 46, 6514148
12-14 years, 8 hours, n=71, 43, 46, 65204410
12-14 years, 12 hours, n=71, 43, 46, 65104410
12-14 years, 18 hours, n=71, 43, 46, 65214410
12-14 years, 24 hours, n=71, 43, 46, 65225610
15-17 years, 1 hour, n=74, 53, 50, 871002
15-17 years, 2 hours, n=74, 53, 50, 876052
15-17 years, 3 hours, n=74, 53, 50, 8718598
15-17 years, 4 hours, n=74, 53, 50, 8720598
15-17 years, 8 hours, n=74, 53, 50, 872551110
15-17 years, 12 hours, n=74, 53, 50, 872871110
15-17 years, 18 hours, n=74, 53, 50, 872991112
15-17 years, 24 hours, n=74, 53, 50, 873091113
SecondaryNumber of Participants Nausea-free at 2 Hours Post-dose

The number of participants who did not have nausea at 2 hours post dose was analzyed.

Time frame:
2 hours after single dose of double-blind treatment (Randomization through Week 13)
Reported as:
Number · participants
Number of Participants Nausea-free at 2 Hours Post-dose
participantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
Total Population, n=144, 95, 96, 1511017874106
12-14 years, n=71, 43, 46, 6555363847
15-17 years, n=73, 52, 50, 8646423659
Other pre-specifiedMean Age of Participants at Baseline Categorized by Age Group

The mean age of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups.

Time frame:
Baseline
Reported as:
Mean · Years
Mean Age of Participants at Baseline Categorized by Age Group
Years12 to 14 Years Age Group15 to 17 Years Age Group
Mean Age of Participants at Baseline Categorized by Age Group13.1 ± 0.7916.1 ± 0.84
Other pre-specifiedNumber of Participants Randomized to Double-blind Treatment in the Indicated Age Categories at Baseline

The number of participants receiving double-blind treatment were reported according to age.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants Randomized to Double-blind Treatment in the Indicated Age Categories at Baseline
ParticipantsPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mg
12-14 years71434665
15-17 years74535187
Other pre-specifiedNumber of Female and Male Participants Categorized by Age Group

The gender of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Female and Male Participants Categorized by Age Group
Participants12 to 14 Years Age Group15 to 17 Years Age Group
Female114173
Male11192
Other pre-specifiedNumber of Participants of the Indicated Race Categorized by Age Group

The race of participants at baseline was reported for all participants in the 12 to 14 year and 15 to 17 year age groups.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants of the Indicated Race Categorized by Age Group
Participants12 to 14 Years Age Group15 to 17 Years Age Group
African American/African Heritage3132
American Indian or Alaska Native10
Asian22
Native Hawaiian or other Pacific Islander10
White181216
African American/African Heritage and White24
American Indian or Alaska Native and White44
Asian and Native Hawaiian/other Pacific Islander01
Asian and White23
Native Hawaiian/ other Pacific Islander and White02
Missing11
Other pre-specifiedMean Weight of Participants at Baseline Categorized by Age Group

The mean weight of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups.

Time frame:
Baseline
Reported as:
Mean · Kilograms (kg)
Mean Weight of Participants at Baseline Categorized by Age Group
Kilograms (kg)12 to 14 Years Age Group15 to 17 Years Age Group
Mean Weight of Participants at Baseline Categorized by Age Group58.7 ± 15.5569.6 ± 17.78
Other pre-specifiedMean Body Mass Index of Participants at Baseline Categorized by Age Group

The mean body mass index of participants at baseline was calculated for all participants in the 12 to 14 year and 15 to 17 year age groups. Body mass index is calculated as: weight (kilograms \[kg\]) divided by height (meters \[m\]\^2).

Time frame:
Baseline
Reported as:
Mean · Kilograms per meters squared (kg/m^2)
Mean Body Mass Index of Participants at Baseline Categorized by Age Group
Kilograms per meters squared (kg/m^2)12 to 14 Years Age Group15 to 17 Years Age Group
Mean Body Mass Index of Participants at Baseline Categorized by Age Group22.6 ± 5.0624.6 ± 5.44

Adverse events

Collected over Serious adverse events (SAEs) and AEs were collected from the start of investigational product (IP) in the Run-In Phase until follow-up (up through 1 week after single dose of double-blind IP for participants who took double-blind IP, up to Week 26).. Non-serious events are listed at a 1.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/145 (0%)3/145 (2.1%)
Sumatriptan 10 mg/ Naproxen 60 mg—0/96 (0%)0/96 (0%)
Sumatriptan 30 mg/ Naproxen 180 mg—0/97 (0%)3/97 (3.1%)
Sumatriptan 85 mg/ Naproxen 500 mg—0/152 (0%)4/152 (2.6%)
Single-blind Run-In Phase Placebo—2/683 (0.3%)11/683 (1.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mgSingle-blind Run-In Phase Placebo
Clavicle fractureInjury, poisoning and procedural complications0/1450/960/970/1521/683
ConcussionInjury, poisoning and procedural complications0/1450/960/970/1521/683
Jaw fractureInjury, poisoning and procedural complications0/1450/960/970/1521/683
Testicular torsionReproductive system and breast disorders0/1450/960/970/1521/683
Most frequent other events
Most frequent other events
EventPlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mgSingle-blind Run-In Phase Placebo
NasopharyngitisInfections and infestations3/1450/961/971/15210/683
Hot flushVascular disorders0/1450/962/971/1521/683
Muscle tightnessMusculoskeletal and connective tissue disorders0/1450/960/973/1520/683

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mgTotal
Mean14.7 ± 1.7614.8 ± 1.8114.7 ± 1.6514.8 ± 1.6914.7 ± 1.72
Gender
Gender(Participants)PlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mgTotal
Female85525694287
Male60444158203
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mgTotal
African American/African Heritage251791263
American Indian or Alaska Native00011
Asian10034
Native Hawaiian or other Pacific Islander10001
White1087584130397
African American/African Heritage and White21126
American Indian or Alaska Native and White12238
Asian and Native Hawaiian/other Pacific Islander10001
Asian and White31015
Native Hawaiian/ other Pacific Islander and White10102
Missing20002
Weight
Weight(Kilograms (kg))PlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mgTotal
Mean63.8 ± 16.6764.2 ± 19.2962.8 ± 14.4966.8 ± 19.1364.6 ± 17.63
Body Mass Index
Body Mass Index(Kilograms per meters squared (kg/m^2))PlaceboSumatriptan 10 mg/ Naproxen 60 mgSumatriptan 30 mg/ Naproxen 180 mgSumatriptan 85 mg/ Naproxen 500 mgTotal
Mean23.5 ± 5.2823.3 ± 5.6222.9 ± 4.5324.6 ± 5.6823.7 ± 5.36
08

Study locations

79 sites
  • GSK Investigational Site
    Gilbert, Arizona 85234, United States
  • GSK Investigational Site
    Litchfield Park, Arizona 85340, United States
  • GSK Investigational Site
    Phoenix, Arizona 85013, United States
  • GSK Investigational Site
    Phoenix, Arizona 85014, United States
  • GSK Investigational Site
    Phoenix, Arizona 85016, United States
  • GSK Investigational Site
    Conway, Arkansas 72034, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72202, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Chico, California 95926, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Fullteron, California 92835, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Newport Beach, California 92660, United States
  • GSK Investigational Site
    Roseville, California 95678, United States
  • GSK Investigational Site
    Sacramento, California 95815, United States
  • GSK Investigational Site
    Sacramento, California 95816, United States
  • GSK Investigational Site
    San Francisco, California 94109, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Fairfield, Connecticut 06824, United States
  • GSK Investigational Site
    Gainesville, Florida 32607, United States
  • GSK Investigational Site
    Hialeah, Florida 33010, United States
  • GSK Investigational Site
    Miami, Florida 33155-3009, United States
  • GSK Investigational Site
    Pensacola, Florida 32504, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Savannah, Georgia 31405, United States
  • GSK Investigational Site
    Stockbridge, Georgia 30281, United States
  • GSK Investigational Site
    Chicago, Illinois 60642, United States
  • GSK Investigational Site
    Oak Lawn, Illinois 60453, United States
  • GSK Investigational Site
    Park Ridge, Illinois 60068, United States
  • GSK Investigational Site
    Anderson, Indiana 46011, United States
  • GSK Investigational Site
    Terre Haute, Indiana 47802, United States
  • GSK Investigational Site
    Kansas City, Kansas 66160, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Bardstown, Kentucky 40004, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Pikesville, Maryland 21208, United States
  • GSK Investigational Site
    Worcester, Massachusetts 01605, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48104, United States
  • GSK Investigational Site
    Plymouth, Minnesota 55441, United States
  • GSK Investigational Site
    Springfield, Missouri 65807, United States
  • GSK Investigational Site
    St. Louis, Missouri 63141, United States
  • GSK Investigational Site
    Omaha, Nebraska 68130, United States
  • GSK Investigational Site
    Henderson, Nevada 89014, United States
  • GSK Investigational Site
    Vorhees, New Jersey 08043, United States
  • GSK Investigational Site
    Willingboro, New Jersey 08046, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87108, United States
  • GSK Investigational Site
    Amherst, New York 14226, United States
  • GSK Investigational Site
    Mineola, New York 11501, United States
  • GSK Investigational Site
    Mount Vernon, New York 10550, United States
  • GSK Investigational Site
    Schenectady, New York 12308, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45245, United States
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
  • GSK Investigational Site
    West Chester, Ohio 45069, United States
  • GSK Investigational Site
    Westerville, Ohio 43081, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Salem, Oregon 97301, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19139, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • GSK Investigational Site
    Greer, South Carolina 29651, United States
  • GSK Investigational Site
    Simpsonville, South Carolina 29681, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Clarksville, Tennessee 37043, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Houston, Texas 77030-2303, United States
  • GSK Investigational Site
    San Antonio, Texas 78258, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84107, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22902, United States
  • GSK Investigational Site
    Norfolk, Virginia 23510, United States
  • GSK Investigational Site
    Seattle, Washington 98195-6097, United States
  • GSK Investigational Site
    Vancouver, Washington 98686, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801, United States
  • GSK Investigational Site
    Madison, Wisconsin 53715, United States
  • GSK Investigational Site
    Middleton, Wisconsin 53562-2215, United States
09

References and documents

Publications

  • Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4;297(13):1443-54. doi: 10.1001/jama.297.13.1443. PubMed 17405970 ↗
  • Derosier FJ, Lewis D, Hershey AD, Winner PK, Pearlman E, Rothner AD, Linder SL, Goodman DK, Jimenez TB, Granberry WK, Runken MC. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics. 2012 Jun;129(6):e1411-20. doi: 10.1542/peds.2011-2455. Epub 2012 May 14. PubMed 22585767 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2009
First posted
Feb 13, 2009
Start
Dec 2008
Primary completionActual
May 2010
CompletionActual
Jun 2010
Results first posted
May 9, 2011
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00843024
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 13, 2009
Start date
Dec 2008
Primary completion
May 2010
Completion
Jun 2010
Results posted
May 9, 2011
Last update
Jan 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sumatriptan · Naproxen

Start the discussion